Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NovoCure's change in receivables for the quarter that ended in Jun. 2026 was R$2 Mil. It means NovoCure's Accounts Receivable
declined by R$2 Mil
from Mar. 2026 to Jun. 2026 .
NovoCure's change in receivables for the fiscal year that ended in Dec. 2025 was R$-212 Mil. It means NovoCure's Accounts Receivable
increased by R$212 Mil
from Dec. 2024 to Dec. 2025 .
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
NovoCure's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 45.46.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. NovoCure's liquidation value for the
three
months ended in Jun. 2026 was R$375 Mil.
NovoCure (BSP:N2VC34) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
NovoCure's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovoCure Change In Receivables Related Terms
NovoCure Change In Receivables Historical Data
* Premium members only.
The historical data trend for NovoCure's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-102 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of R$-102 Mil mean?
NovoCure (BSP:N2VC34) has a Change In Receivables of R$-102 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for NovoCure and its competitors.
Is NovoCure's Change In Receivables too high?
NovoCure's current Change In Receivables is R$-102 Mil. Overall, NovoCure has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's Change In Receivables compare to NEOG and AXGN?
NovoCure's Change In Receivables of R$-102 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for NovoCure and its competitors. NovoCure's current Change In Receivables is R$-102 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (BSP:N2VC34) is currently considered Fairly Valued. The stock's GF Value™ is R$8.49, compared to a current price of R$7.98 — trading 6% below its estimated fair value. The current Change In Receivables is R$-102 Mil. NovoCure's overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For NovoCure (BSP:N2VC34), the current Change In Receivables is R$-102 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NovoCure (BSP:N2VC34) Overvalued in 2026?
Based on GuruFocus' analysis, NovoCure stock appears to be undervalued.
The current stock price of R$7.98 is trading 6% below its estimated GF Value™ of R$8.49.
GuruFocus considers NovoCure to be Fairly Valued.
Key valuation signals for BSP:N2VC34:
Change In Receivables: R$-102 Mil
GF Value™: R$8.49 vs. price of R$7.98 (6% below fair value)
No single metric tells the full story. See the BSP:N2VC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
48GF Score
Get the complete analysis for BSP:N2VC34
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:N2VC34 has been successfully added to your 
